These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

223 related articles for article (PubMed ID: 18818521)

  • 21. Cytoplasmic tethering is involved in synergistic inhibition of p53 by Mdmx and Mdm2.
    Ohtsubo C; Shiokawa D; Kodama M; Gaiddon C; Nakagama H; Jochemsen AG; Taya Y; Okamoto K
    Cancer Sci; 2009 Jul; 100(7):1291-9. PubMed ID: 19432880
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Benzimidazoles Downregulate Mdm2 and MdmX and Activate p53 in MdmX Overexpressing Tumor Cells.
    Mrkvová Z; Uldrijan S; Pombinho A; Bartůněk P; Slaninová I
    Molecules; 2019 Jun; 24(11):. PubMed ID: 31181622
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The Zn-finger domain of MdmX suppresses cancer progression by promoting genome stability in p53-mutant cells.
    Matijasevic Z; Krzywicka-Racka A; Sluder G; Gallant J; Jones SN
    Oncogenesis; 2016 Oct; 5(10):e262. PubMed ID: 27694836
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Molecular basis for the inhibition of p53 by Mdmx.
    Popowicz GM; Czarna A; Rothweiler U; Szwagierczak A; Krajewski M; Weber L; Holak TA
    Cell Cycle; 2007 Oct; 6(19):2386-92. PubMed ID: 17938582
    [TBL] [Abstract][Full Text] [Related]  

  • 25. MDM2 and MDMX promote ferroptosis by PPARα-mediated lipid remodeling.
    Venkatesh D; O'Brien NA; Zandkarimi F; Tong DR; Stokes ME; Dunn DE; Kengmana ES; Aron AT; Klein AM; Csuka JM; Moon SH; Conrad M; Chang CJ; Lo DC; D'Alessandro A; Prives C; Stockwell BR
    Genes Dev; 2020 Apr; 34(7-8):526-543. PubMed ID: 32079652
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Functions of MDMX in the modulation of the p53-response.
    Lenos K; Jochemsen AG
    J Biomed Biotechnol; 2011; 2011():876173. PubMed ID: 21541195
    [TBL] [Abstract][Full Text] [Related]  

  • 27. mdmx is a negative regulator of p53 activity in vivo.
    Finch RA; Donoviel DB; Potter D; Shi M; Fan A; Freed DD; Wang CY; Zambrowicz BP; Ramirez-Solis R; Sands AT; Zhang N
    Cancer Res; 2002 Jun; 62(11):3221-5. PubMed ID: 12036937
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The past, present and future of potential small-molecule drugs targeting p53-MDM2/MDMX for cancer therapy.
    Liu Y; Wang X; Wang G; Yang Y; Yuan Y; Ouyang L
    Eur J Med Chem; 2019 Aug; 176():92-104. PubMed ID: 31100649
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Elevated MDM2 boosts the apoptotic activity of p53-MDM2 binding inhibitors by facilitating MDMX degradation.
    Xia M; Knezevic D; Tovar C; Huang B; Heimbrook DC; Vassilev LT
    Cell Cycle; 2008 Jun; 7(11):1604-12. PubMed ID: 18520179
    [TBL] [Abstract][Full Text] [Related]  

  • 30. A site-directed mutagenesis study of the MdmX RING domain.
    Egorova O; Mis M; Sheng Y
    Biochem Biophys Res Commun; 2014 May; 447(4):696-701. PubMed ID: 24755078
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The p53 inhibitors MDM2/MDMX complex is required for control of p53 activity in vivo.
    Huang L; Yan Z; Liao X; Li Y; Yang J; Wang ZG; Zuo Y; Kawai H; Shadfan M; Ganapathy S; Yuan ZM
    Proc Natl Acad Sci U S A; 2011 Jul; 108(29):12001-6. PubMed ID: 21730163
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Overexpression of Mdm2 and MdmX fusion proteins alters p53 mediated transactivation, ubiquitination, and degradation.
    Ghosh M; Huang K; Berberich SJ
    Biochemistry; 2003 Mar; 42(8):2291-9. PubMed ID: 12600196
    [TBL] [Abstract][Full Text] [Related]  

  • 33. p53 binds the mdmx mRNA and controls its translation.
    Tournillon AS; López I; Malbert-Colas L; Findakly S; Naski N; Olivares-Illana V; Karakostis K; Vojtesek B; Nylander K; Fåhraeus R
    Oncogene; 2017 Feb; 36(5):723-730. PubMed ID: 27375027
    [TBL] [Abstract][Full Text] [Related]  

  • 34. The role of miRNAs in MDMX-p53 interplay.
    Yu D; Xu Z; Cheng X; Qin J
    J Evid Based Med; 2021 May; 14(2):152-160. PubMed ID: 33988919
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Dual inhibition of MDMX and MDM2 as a therapeutic strategy in leukemia.
    Carvajal LA; Neriah DB; Senecal A; Benard L; Thiruthuvanathan V; Yatsenko T; Narayanagari SR; Wheat JC; Todorova TI; Mitchell K; Kenworthy C; Guerlavais V; Annis DA; Bartholdy B; Will B; Anampa JD; Mantzaris I; Aivado M; Singer RH; Coleman RA; Verma A; Steidl U
    Sci Transl Med; 2018 Apr; 10(436):. PubMed ID: 29643228
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Induction of p53 expression and apoptosis by a recombinant dual-target MDM2/MDMX inhibitory protein in wild-type p53 breast cancer cells.
    Geng QQ; Dong DF; Chen NZ; Wu YY; Li EX; Wang J; Wang SM
    Int J Oncol; 2013 Dec; 43(6):1935-42. PubMed ID: 24126697
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Efficient reactivation of p53 in cancer cells by a dual MdmX/Mdm2 inhibitor.
    Qin L; Yang F; Zhou C; Chen Y; Zhang H; Su Z
    J Am Chem Soc; 2014 Dec; 136(52):18023-33. PubMed ID: 25453499
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Aberrant activation of p53 due to loss of MDM2 or MDMX causes early lens dysmorphogenesis.
    Zhang Y; Zhang X; Lu H
    Dev Biol; 2014 Dec; 396(1):19-30. PubMed ID: 25263199
    [TBL] [Abstract][Full Text] [Related]  

  • 39. MDM2, MDMX and p53 in oncogenesis and cancer therapy.
    Wade M; Li YC; Wahl GM
    Nat Rev Cancer; 2013 Feb; 13(2):83-96. PubMed ID: 23303139
    [TBL] [Abstract][Full Text] [Related]  

  • 40. The MDM2-a splice variant of MDM2 alters transformation in vitro and the tumor spectrum in both Arf- and p53-null models of tumorigenesis.
    Volk EL; Fan L; Schuster K; Rehg JE; Harris LC
    Mol Cancer Res; 2009 Jun; 7(6):863-9. PubMed ID: 19491200
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.